This is the authors' abstract. We don't add key points for this paper.
Biopolymers emerge as potential adaptable platforms that merge mechanical support with finely tuned immune regulation in VCA. Successful translation will depend on tissue-specific material optimization, standardized immunological endpoints, and multicenter studies that replicate clinical complexity. Drawing on lessons from solid-organ transplantation and fostering collaboration among immunologists, biomaterial scientists, and surgeons will be pivotal to moving these technologies from bench to bedside in VCA.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Knoedler et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: